Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DRUG
stocks logo

DRUG

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
--
--
-0.978
+475%
--
--
-1.220
-12300%
Estimates Revision
The market is revising No Change the revenue expectations for Bright Minds Biosciences Inc. (DRUG) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 71.64%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+71.64%
In Past 3 Month
Wall Street analysts forecast DRUG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRUG is 79.10 USD with a low forecast of 71.49 USD and a high forecast of 84.40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast DRUG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRUG is 79.10 USD with a low forecast of 71.49 USD and a high forecast of 84.40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 72.500
sliders
Low
71.49
Averages
79.10
High
84.40
Current: 72.500
sliders
Low
71.49
Averages
79.10
High
84.40
Baird
NULL -> Outperform
maintain
$75 -> $82
2025-11-07
Reason
Baird
Price Target
$75 -> $82
2025-11-07
maintain
NULL -> Outperform
Reason
Baird raised the firm's price target on Bright Minds to $82 from $75 and keeps an Outperform rating on the shares. The firm updated its model as the BMB-105 Pader-Willi program holds promise.
BTIG
initiated
$72
2025-09-08
Reason
BTIG
Price Target
$72
2025-09-08
initiated
Reason
BTIG initiated coverage of Bright Minds with a Buy rating and $72 price target. The company is developing a "very specific" 5-HT2C agonist, BMB-101, for epilepsies that has better dosing than bexicaserin, the analyst tells investors in a research note. The firm believes the dosing advantage is relevant given data suggesting the side effects of the 5-HT2C class may be peak concentration-dependent. The relatively high percentage of absence seizures in otherwise healthy children suggests convenient dosing and low side effects "are a major positive," contends BTIG. It expects Phase 2 data from Bright Minds around year-end 2025.
Cantor Fitzgerald
Overweight
initiated
2025-07-02
Reason
Cantor Fitzgerald
Price Target
2025-07-02
initiated
Overweight
Reason
Cantor Fitzgerald assumed coverage of Bright Minds with an Overweight rating and no price target. Bright Minds' lead asset, BMB-101, is a highly selective 5-HT2C receptor agonist in developmental and epileptic encephalopathies and absence epilepsy, the analyst tells investors in a research note. BMB-101 may deliver improved efficacy, safety, and durability vs. competitors, the firm says.
TD Cowen
Joseph Thome
Buy
initiated
2025-05-13
Reason
TD Cowen
Joseph Thome
Price Target
2025-05-13
initiated
Buy
Reason
TD Cowen analyst Joseph Thome initiated coverage of Bright Minds with a Buy rating and no price target. The company's lead asset BMB-101 is a biased 5-HT2C agonist that has the potential to be best in class for the treatment of certain refractory seizure disorders, the analyst tells investors in a research note. The firm says its key opinion leaders have highlighted the unmet need by current options in absence epilepsy.
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$85
2025-02-19
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$85
2025-02-19
Reiterates
Strong Buy
Reason
Piper Sandler
Yasmeen Rahimi
Buy
Initiates
$93
2025-01-23
Reason
Piper Sandler
Yasmeen Rahimi
Price Target
$93
2025-01-23
Initiates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Bright Minds Biosciences Inc (DRUG.O) is -18.22, compared to its 5-year average forward P/E of -3.56. For a more detailed relative valuation and DCF analysis to assess Bright Minds Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.56
Current PE
-18.22
Overvalued PE
3.98
Undervalued PE
-11.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.32
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.43
Undervalued EV/EBITDA
-4.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

DRUG News & Events

Events Timeline

(ET)
2025-09-04
08:33:31
Bright Minds reports that BMB-201 surpasses sumatriptan in preclinical studies.
select
2025-05-15 (ET)
2025-05-15
14:49:05
VA secretary wants to find answers on psychedelics therapies, Politico says
select
link
2025-05-13 (ET)
2025-05-13
08:42:28
Bright Minds announces findings from mouse model study of BMB-101
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-26NASDAQ.COM
Understanding the Recent Price Movement of Bright Minds Biosciences Inc. (DRUG) and Its Benefits

  • Trend Investing Insights: Successful short-term investing relies on timing entries into trends and confirming the sustainability of those trends through sound fundamentals and positive earnings estimates.

  • Bright Minds Biosciences Inc. (DRUG): DRUG has shown a significant price increase of 68.9% over 12 weeks and 14.1% over the last four weeks, indicating a strong upward trend, and it is currently trading at 90% of its 52-week high-low range.

  • Zacks Rank and Broker Recommendations: DRUG holds a Zacks Rank #2 (Buy) and an Average Broker Recommendation of #1 (Strong Buy), suggesting strong optimism about its near-term price performance.

  • AI Investment Opportunities: The next phase of AI growth is expected to create substantial wealth for early investors, with Zacks highlighting four under-the-radar companies poised for significant advancements in AI.

[object Object]
Preview
1.0
11-26Newsfilter
Bright Minds Biosciences to Attend Two Major Healthcare Conferences Focused on CNS Disorders
  • Conference Participation: Bright Minds Biosciences will participate in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, showcasing its innovative advancements in treating drug-resistant epilepsy and depression, aiming to attract investor interest in its unique therapeutic platform.
  • Scientific Exhibit: The company will also present at the American Epilepsy Society Annual Meeting on December 7, 2025, highlighting its latest research in central nervous system disorders, further enhancing its visibility and influence in the biotechnology sector.
  • Innovative Platform: Bright Minds focuses on developing highly selective 5-HT2 agonists to address high unmet medical needs in neurology and psychiatry, driving the company's long-term growth potential in the biopharmaceutical industry.
  • Investor Relations: By actively participating in industry conferences, the company enhances its interaction with investors, showcasing its R&D capabilities in neuroscience, aiming to attract more capital to support the development of its innovative drugs.
[object Object]
Preview
6.5
11-25NASDAQ.COM
Wall Street Experts Predict a 36.27% Increase for Bright Minds Biosciences Inc. (DRUG): Important Insights Before You Invest

  • Stock Performance and Price Targets: Bright Minds Biosciences Inc. (DRUG) shares have risen 2.9% recently, with Wall Street analysts projecting a mean price target of $82.4, suggesting a potential upside of 36.3%. The price targets range from $72.00 to $93.00, indicating varying levels of optimism among analysts.

  • Skepticism Towards Price Targets: While price targets can provide insights, relying solely on them for investment decisions is cautioned against, as analysts may set overly optimistic targets influenced by business relationships, leading to potential misguidance for investors.

  • Earnings Estimate Revisions: Analysts show growing optimism regarding DRUG's earnings, with a 6.1% increase in the Zacks Consensus Estimate over the past month, indicating a positive trend that could correlate with stock price movements.

  • Investment Considerations: Despite the skepticism surrounding price targets, the strong agreement among analysts on earnings revisions and DRUG's favorable Zacks Rank #2 (Buy) suggests a legitimate potential for stock upside, warranting further research by investors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Bright Minds Biosciences Inc (DRUG) stock price today?

The current price of DRUG is 72.5 USD — it has decreased -2.11 % in the last trading day.

arrow icon

What is Bright Minds Biosciences Inc (DRUG)'s business?

Bright Minds Biosciences Inc. is a biotechnology company, which is engaged in developing treatments for patients with neurological and psychiatric disorders. The Company is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.

arrow icon

What is the price predicton of DRUG Stock?

Wall Street analysts forecast DRUG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRUG is 79.10 USD with a low forecast of 71.49 USD and a high forecast of 84.40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Bright Minds Biosciences Inc (DRUG)'s revenue for the last quarter?

Bright Minds Biosciences Inc revenue for the last quarter amounts to -3.29M USD, decreased -1493.23 % YoY.

arrow icon

What is Bright Minds Biosciences Inc (DRUG)'s earnings per share (EPS) for the last quarter?

Bright Minds Biosciences Inc. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Bright Minds Biosciences Inc (DRUG)'s fundamentals?

The market is revising No Change the revenue expectations for Bright Minds Biosciences Inc. (DRUG) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 71.64%.
arrow icon

How many employees does Bright Minds Biosciences Inc (DRUG). have?

Bright Minds Biosciences Inc (DRUG) has 0 emplpoyees as of December 05 2025.

arrow icon

What is Bright Minds Biosciences Inc (DRUG) market cap?

Today DRUG has the market capitalization of 513.93M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free